SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus: into single digits
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MIKE DUBIS who wrote (643)6/30/1998 10:13:00 PM
From: VLAD  Read Replies (1) of 1016
 
MIKE,

If I were in charge of Vivus here is what I would do ASAP. I would sell the company in 3 parts. One part goes to Astra and it's territory. The second goes to Janssen and it's territory and the third goes to any large pharmaceutical who wants to buy rights to the US and Japan. The factory operations can be run by all 3 companies each sharing in the porportional costs of units required. Future research and development of intraurethral products could also be shared for each companies territory.

I believe that this company is much more valuable cut into 3 parts rather than sold as a whole. I think that Vivus could easily get $6.00 for each territory. But Vivus would not dare do this. Do you know why? It is because Vivus thinks it is worth at least $30.00 a share and not less than $20.00.

Would have this been a prudent choice at this time? Only time will tell.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News